Beyfortus: Dosage Form, Projected Sales, NCE-1 Date | Nirsevimab-Alip

Beyfortus

Beyfortus is a single-dose antibody given to newborns and infants to prevent serious RSV (respiratory syncytial virus) lung infections during their first two RSV seasons. It reduces hospitalizations by about 70 to 80%.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Nirsevimab-Alip
Innovator :

SANOFI
Approval Date :

17-Jul-23
Data Exclusivity Expiry :

17-Jul-27
Market Exclusivity Expiry :

17-Jul-35
Dosage Form :

Intramuscular Injection
Strength :

100mg/ 1ml and 50mg/ 0.5ml
Therapeutic Category :

Antiviral
Revenue ($M) :

2,346

Year-wise Projected Sales ($M) :

2025 :

2,606
2026 :

2,914
2027 :

3,168
2028 :

3,382
2029 :

3,536
2030 :

3,699
2031 :

3,862

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Beyfortus

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?